Jamie is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. Throughout his 12 years as a General Partner, Jamie has invested across over 20 companies encompassing a broad spectrum of Life Science and Biopharmaceutical companies.
Jamie has led and served as a board member for many of Frazier’s successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Calistoga Pharmaceuticals (co-founder, sold to Gilead), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), CoTherix (sold to Actelion), and Threshold (NASDAQ: THLD). He currently represents Frazier on the boards of Alcresta Therapeutics, Allena Pharmaceuticals, Alpine Immune Sciences, AnaptysBio, Aptinyx, Entasis Therapeutics, Millendo Therapeutics (formerly Atterocor), and Sierra Oncology (NASDAQ: SRRA).
Prior to joining Frazier, Jamie served as head of the cardiovascular research and development franchise at Millennium Pharmaceuticals. Before the merger of COR Therapeutics and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the faculties of Stanford Medical School and Harvard Medical School prior to joining COR.
Jamie received his MD and PhD in Biophysics from Stanford University School of Medicine and holds a B.S. from the University of Michigan. He did his postgraduate training in Internal Medicine and Cardiovascular Disease at the Brigham and Women’s Hospital in Boston. In 2011 and 2016, Jamie was named to the Midas List of leading venture capitalists.